Cytochrome P450 reductase dependent inhibition of cytochrome P450 2B1 activity: Implications for gene directed enzyme prodrug therapy

Biochemical Pharmacology

Volumn 72, Issue 7, 2006, Pages 893-901

  Lengler, Johannes ^a   Omann, Markus ^b   Düvier, Dana ^b   Holzmüller, Harry ^a   Gregor, Wolfgang ^b   Salmons, Brian ^a   Günzburg, Walter H ^b   Renner, Matthias ^a  

^a Austrianova Biomanufacturing Company   (Austria)

^b UNIVERSITY OF VETERINARY MEDICINE   (Austria)

Author keywords

CYP2B1; Cytochrome P450; Cytochrome P450 reductase; Ifosfamide; P450 GDEPT

Indexed keywords

4 HYDROXYIFOSFAMIDE; CYTOCHROME C; CYTOCHROME P450 2B1; CYTOCHROME P450 REDUCTASE; DRUG METABOLITE; IFOSFAMIDE; PLASMID VECTOR; PRODRUG; RESORUFIN; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; BREAST TUMOR; CELL ASSAY; CELL STRAIN 3T3; CELL STRAIN HEK293; CELL TYPE; CELL VIABILITY; CONTROLLED STUDY; DRUG DETERMINATION; DRUG EFFECT; EMBRYO; ENZYME ACTIVITY; ENZYME INHIBITION; FEMALE; GENE DIRECTED ENZYME PRODRUG THERAPY; GENE THERAPY; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PANCREAS TUMOR; PRIORITY JOURNAL; PROTEIN EXPRESSION; THERAPY EFFECT; TUMOR CELL CULTURE; TUMOR CELL LINE; WESTERN BLOTTING;

ANIMALS; ANTINEOPLASTIC AGENTS, ALKYLATING; BLOTTING, WESTERN; CELL LINE; CELL LINE, TUMOR; CELL SURVIVAL; CYTOCHROME C GROUP; CYTOCHROME P-450 CYP2B1; DOSE-RESPONSE RELATIONSHIP, DRUG; GENE THERAPY; HUMANS; IFOSFAMIDE; MICE; NADPH-FERRIHEMOPROTEIN REDUCTASE; NIH 3T3 CELLS; OXAZINES; PLASMIDS; PRODRUGS; TRANSFECTION;

EID: 33748071125     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bcp.2006.06.012     Document Type: Article

References (31)

1. Nelson D.R., Kamataki T., Waxman D.J., Guengerich F.P., Estabrook R.W., Feyereisen R., et al. The P450 superfamily: update on new sequences, gene mapping, accession numbers, early trivial names of enzymes, and nomenclature. DNA Cell Biol 12 (1993) 1-51
2. Yu L.J., Matias J., Scudiero D.A., Hite K.M., Monks A., Sausville E.A., et al. P450 enzyme expression patterns in the NCI human tumor cell line panel. Drug Metab Dispos 29 (2001) 304-312
3. Löhr M., Müller P., Karle P., Stange J., Mitzner S., Jesnowski R., et al. Targeted chemotherapy by intratumour injection of encapsulated cells engineered to produce CYP2B1, an ifosfamide activating cytochrome P450. Gene Ther 5 (1998) 1070-1078
4. Le Blanc G.A., and Waxman D.J. Interaction of anticancer drugs with hepatic monooxygenase enzymes. Drug Metab Rev 20 (1989) 395-439
5. Peterson J.A., Ebel R.E., O'Keeffe D.H., Matsubara T., and Estabrook R.W. Temperature dependence of cytochrome P-450 reduction. A model for NADPH-cytochrome P-450 reductase:cytochrome P-450 interaction. J Biol Chem 251 (1976) 4010-4016
6. Sengstag C., Eugster H.P., and Wurgler F.E. High promutagen activating capacity of yeast microsomes containing human cytochrome P-450 1A and human NADPH-cytochrome P-450 reductase. Carcinogenesis 15 (1994) 837-843
7. Chen L., Yu L.J., and Waxman D.J. Potentiation of cytochrome P450/cyclophosphamide-based cancer gene therapy by coexpression of the P450 reductase gene. Cancer Res 57 (1997) 4830-4837
8. Wang X.J., Chamberlain M., Vassieva O., Henderson C.J., and Wolf C.R. Relationship between hepatic phenotype and changes in gene expression in cytochrome P450 reductase (POR) null mice. Biochem J 388 (2005) 857-867
9. Li D.N., Pritchard M.P., Hanlon S.P., Burchell B., Wolf C.R., and Friedberg T. Competition between cytochrome P-450 isozymes for NADPH-cytochrome P-450 oxidoreductase affects drug metabolism. J Pharmacol Exp Ther 289 (1999) 661-667
10. Schmalix W.A., Lang D., Schneider A., Bocker R., Greim H., and Doehmer J. Stable expression and coexpression of human cytochrome P450 oxidoreductase and cytochrome P450 1A2 in V79 Chinese hamster cells: sensitivity to quinones and biotransformation of 7-alkoxyresorufins and triazines. Drug Metab Dispos 24 (1996) 1314-1319
11. Schneider A., Schmalix W.A., Siruguri V., de Groene E.M., Horbach G.J., Kleingeist B., et al. Stable expression of human cytochrome P450 3A4 in conjunction with human NADPH-cytochrome P450 oxidoreductase in V79 Chinese hamster cells. Arch Biochem Biophys 332 (1996) 295-304
12. Ding S., Yao D., Burchell B., Wolf C.R., and Friedberg T. High levels of recombinant CYP3A4 expression in Chinese hamster ovary cells are modulated by coexpressed human P450 reductase and hemin supplementation. Arch Biochem Biophys 348 (1997) 403-410
13. Lengler J., Holzmüller H., Salmons B., Günzburg W.H., and Renner M. FMDV-2A sequence and protein arrangement contribute to functionality of CYP2B1-reporter fusion protein. Anal Biochem 343 (2005) 116-124
14. Klein R., Ruttkowski B., Knapp E., Salmons B., Günzburg W.H., and Hohenadl C. WPRE-mediated enhancement of gene expression is promoter and cell line specific. Gene 372 (2006) 153-161
15. Klein D., Indraccolo S., von Rombs K., Amadori A., Salmons B., and Günzburg W.H. Rapid identification of viable retrovirus-transduced cells using the green fluorescent protein as a marker. Gene Ther 4 (1997) 1256-1260
16. Pambalk K., Hohenadl C., Salmons B., Günzburg W.H., and Renner M. Specific packaging of spliced retroviral vector transcripts lacking the Psi-region. Biochem Biophys Res Commun 293 (2002) 239-246
17. Graham F.L., Smiley J., Russell W.C., and Nairn R. Characteristics of a human cell line transformed by DNA from human adenovirus type 5. J Gen Virol 36 (1977) 59-74
18. Jaffee E.M., Schutte M., Gossett J., Morsberger L.A., Adler A.J., Thomas M., et al. Development and characterization of a cytokine-secreting pancreatic adenocarcinoma vaccine from primary tumors for use in clinical trials. Cancer J Sci Am 4 (1998) 194-203
19. Lieber M., Mazzetta J., Nelson-Rees W., Kaplan M., and Todaro G. Establishment of a continuous tumor-cell line (panc-1) from a human carcinoma of the exocrine pancreas. Int J Cancer 15 (1975) 741-747
20. Jainchill J.L., Aaronson S.A., and Todaro G.J. Murine sarcoma and leukemia viruses: assay using clonal lines of contact-inhibited mouse cells. J Virol 4 (1969) 549-553
21. Hackett A.J., Smith H.S., Springer E.L., Owens R.B., Nelson-Rees W.A., Riggs J.L., et al. Two syngeneic cell lines from human breast tissue: the aneuploid mammary epithelial (Hs578T) and the diploid myoepithelial (Hs578Bst) cell lines. J Natl Cancer Inst 58 (1977) 1795-1806
22. Judge S.M., and Chatterton Jr. R.T. Progesterone-specific stimulation of triglyceride biosynthesis in a breast cancer cell line (T-47D). Cancer Res 43 (1983) 4407-4412
23. Schwartz P.S., Chen C.S., and Waxman D.J. Sustained P450 expression and prodrug activation in bolus cyclophosphamide-treated cultured tumor cells. Impact of prodrug schedule on P450 gene-directed enzyme prodrug therapy. Cancer Gene Ther 10 (2003) 571-582
24. Omura T., and Sato R. The carbon monoxide-binding pigment of liver microsomes. I. Evidence for its hemoprotein nature. J Biol Chem 239 (1964) 2370-2378
25. Russo J.E., and Hilton J. Characterization of cytosolic aldehyde dehydrogenase from cyclophosphamide resistant L1210 cells. Cancer Res 48 (1988) 2963-2968
26. Hilton J. Role of aldehyde dehydrogenase in cyclophosphamide-resistant L1210 leukemia. Cancer Res 44 (1984) 5156-5160
27. Chen L., and Waxman D.J. Intratumoral activation and enhanced chemotherapeutic effect of oxazaphosphorines following cytochrome P-450 gene transfer: development of a combined chemotherapy/cancer gene therapy strategy. Cancer Res 55 (1995) 581-589
28. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?CMD=search&DB=unigene
29. Huang Z., Raychowdhury M.K., and Waxman D.J. Impact of liver P450 reductase suppression on cyclophosphamide activation, pharmacokinetics and antitumoral activity in a cytochrome P450-based cancer gene therapy model. Cancer Gene Ther 7 (2000) 1034-1042
30. Henderson C.J., Otto D.M., Carrie D., Magnuson M.A., McLaren A.W., Rosewell I., et al. Inactivation of the hepatic cytochrome P450 system by conditional deletion of hepatic cytochrome P450 reductase. J Biol Chem 278 (2003) 13480-13486
31. Tychopoulos M., Corcos L., Genne P., Beaune P., and de Waziers I. A virus-directed enzyme prodrug therapy (VDEPT) strategy for lung cancer using a CYP2B6/NADPH-cytochrome P450 reductase fusion protein. Cancer Gene Ther 12 (2005) 497-508